Hanmi Pharm. Co., Ltd. (KRX:128940)
South Korea · Delayed Price · Currency is KRW 400,000
-28,500 (-6.65%)
Last updated: Jun 10, 2026, 2:01 PM KST
Hanmi Pharm. Cash Flow Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 172,439 | 169,554 | 121,315 | 146,231 | 82,792 | 67,025 |
Depreciation & Amortization | 99,029 | 98,809 | 97,331 | 98,454 | 96,842 | 89,086 |
Loss (Gain) From Sale of Assets | -16.26 | -101.2 | -27.74 | -1,769 | -451.65 | 1,062 |
Asset Writedown & Restructuring Costs | 3,088 | 3,013 | 2,488 | 9,153 | 3,794 | 535.2 |
Loss (Gain) From Sale of Investments | -4,329 | -4,762 | 87.92 | -2,630 | -47.09 | - |
Loss (Gain) on Equity Investments | 18.91 | 7.45 | 9.2 | -1,258 | 8,537 | 4.02 |
Provision & Write-off of Bad Debts | 3,334 | 3,346 | -593.89 | 1,277 | 723.06 | 5,118 |
Other Operating Activities | 58,210 | 53,274 | 63,140 | 24,476 | 43,766 | 92,609 |
Change in Accounts Receivable | -74,088 | -87,255 | -61,052 | -3,217 | 37,286 | -76,613 |
Change in Inventory | -73,906 | -37,035 | 1,928 | -16,903 | -14,365 | 18,916 |
Change in Accounts Payable | 16,622 | 12,458 | -10,438 | 5,574 | -2,736 | 9,794 |
Change in Other Net Operating Assets | 4,966 | -38,238 | -20,701 | -42,852 | -93,870 | -5,613 |
Operating Cash Flow | 205,368 | 173,072 | 193,487 | 216,538 | 162,269 | 201,923 |
Operating Cash Flow Growth | 41.53% | -10.55% | -10.64% | 33.44% | -19.64% | 33.25% |
Capital Expenditures | -51,451 | -43,025 | -39,261 | -27,352 | -30,378 | -19,949 |
Sale of Property, Plant & Equipment | 322.35 | 462.72 | 50.86 | 2,600 | 1,397 | 86.37 |
Sale (Purchase) of Intangibles | -29,967 | -32,997 | -22,768 | -16,156 | -20,273 | -14,199 |
Investment in Securities | 38,113 | -53,626 | 103,827 | -138,865 | -118,609 | -6,953 |
Other Investing Activities | -4,569 | -3,974 | -3,650 | -3,699 | -13,545 | -2,375 |
Investing Cash Flow | -82,402 | -159,455 | 24,851 | -183,472 | -181,408 | -43,389 |
Short-Term Debt Issued | - | 142,400 | 431,830 | 134,650 | 230,000 | 102,700 |
Long-Term Debt Issued | - | 38,000 | 49,000 | - | 7,000 | 30,000 |
Total Debt Issued | 177,900 | 180,400 | 480,830 | 134,650 | 237,000 | 132,700 |
Short-Term Debt Repaid | - | -193,500 | -472,330 | -202,650 | -116,800 | -198,800 |
Long-Term Debt Repaid | - | -53,234 | -86,431 | -37,720 | -147,240 | -36,476 |
Total Debt Repaid | -236,826 | -246,734 | -558,761 | -240,370 | -264,040 | -235,276 |
Net Debt Issued (Repaid) | -58,926 | -66,334 | -77,931 | -105,720 | -27,040 | -102,576 |
Issuance of Common Stock | 0 | 0 | - | - | - | - |
Repurchase of Common Stock | - | - | -3,280 | -3,071 | -3,834 | -4,874 |
Dividends Paid | -14,358 | -30,855 | -12,555 | -17,996 | -5,992 | -5,881 |
Other Financing Activities | -0 | - | - | -0 | - | - |
Financing Cash Flow | -73,285 | -97,190 | -93,767 | -126,787 | -36,867 | -113,331 |
Foreign Exchange Rate Adjustments | 6,361 | -431.32 | 12,727 | 1,373 | -5,890 | 17,864 |
Net Cash Flow | 56,043 | -84,004 | 137,297 | -92,348 | -61,896 | 63,067 |
Free Cash Flow | 153,918 | 130,048 | 154,226 | 189,186 | 131,890 | 181,974 |
Free Cash Flow Growth | 38.45% | -15.68% | -18.48% | 43.44% | -27.52% | 65.85% |
Free Cash Flow Margin | 9.93% | 8.40% | 10.31% | 12.69% | 9.90% | 15.12% |
Free Cash Flow Per Share | 12128.64 | 10248.77 | 12162.13 | 14906.67 | 10382.37 | 14307.73 |
Cash Interest Paid | 14,355 | 17,060 | 24,747 | 27,846 | 19,498 | 18,315 |
Cash Income Tax Paid | 38,829 | 46,290 | 22,120 | 31,432 | 29,632 | 6,599 |
Levered Free Cash Flow | 35,940 | 2,284 | 132,235 | 156,408 | 193,044 | 159,618 |
Unlevered Free Cash Flow | 45,497 | 12,901 | 147,468 | 174,226 | 207,199 | 169,979 |
Change in Working Capital | -126,405 | -150,069 | -90,263 | -57,397 | -73,686 | -53,516 |